Is Target a Dividend King?
Popular retail giant Target Corporation (NYSE:TGT) has been in a…
Buy
57
NVOS Quote, Financials, Valuation and Earnings
Last price:
$0.09
Seasonality move
:
42.92%
Day range:
$0.09 - $0.10
52-week range:
$0.03 - $1.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.12x
P/B ratio:
0.19x
Volume:
143.8K
Avg. volume:
152.4K
1-year change:
-88.03%
Market cap:
$1.9M
Revenue:
$12.6M
EPS (TTM):
-$0.67
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Novo Integrated Sciences has -- downside to fair value with a price target of -- per share.
NVOS vs. S&P 500
-
Over the past 5 trading days, Novo Integrated Sciences has overperformed the S&P 500 by 91.11% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novo Integrated Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Integrated Sciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Novo Integrated Sciences reported revenues of $3.2M.
Earnings Growth
-
Novo Integrated Sciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Novo Integrated Sciences reported earnings per share of -$0.16.
Enterprise value:
2.7M
EV / Invested capital:
--
Price / LTM sales:
0.12x
EV / EBIT:
--
EV / Revenue:
0.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$5.5M
Return On Assets:
-33.57%
Net Income Margin (TTM):
-88.48%
Return On Equity:
-49.15%
Return On Invested Capital:
-44.59%
Operating Margin:
-48.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-05-31 | 2023-05-31 | 2024-05-31 | 2023-05-31 | 2024-05-31 | |
| Income Statement | ||||||
| Revenue | $22.6M | $1.1M | $13.5M | $3.3M | $3.2M | |
| Gross Profit | $5.9M | $3.9M | $5.1M | $1.3M | $896.9K | |
| Operating Income | -$6.5M | -$10.4M | -$10.5M | -$1.4M | -$2.5M | |
| EBITDA | -$3.9M | -$23.5M | -$16M | -$740.1K | -$10.1M | |
| Diluted EPS | -$4.50 | -$9.43 | -$1.31 | -$0.10 | -$0.74 | |
| Period Ending | 2020-05-31 | 2021-05-31 | 2022-05-31 | 2023-05-31 | 2024-05-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.9M | $10.8M | $20.1M | $4M | $6.2M | |
| Total Assets | $36.6M | $42.2M | $71.8M | $35.7M | $35.3M | |
| Current Liabilities | $2.5M | $3.5M | $12.7M | $6.2M | $22.7M | |
| Total Liabilities | $6M | $5.6M | $27.4M | $9.5M | $25.7M | |
| Total Equity | $30.6M | $36.6M | $44.4M | $26.3M | $9.7M | |
| Total Debt | $1.2M | $1.2M | $19M | $2.3M | $2.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-05-31 | 2023-05-31 | 2024-05-31 | 2023-05-31 | 2024-05-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.3M | -$1.3M | -$4.8M | -$857.7K | -$658K | |
| Cash From Investing | $3.8M | -- | -- | -$18.9K | -$2K | |
| Cash From Financing | $8M | -$10.9M | $5.6M | $901K | $1.8M | |
| Free Cash Flow | -$7.6M | -$1.4M | -$4.8M | -$876.6K | -$660K | |
NVOS
Sector
Market Cap
$1.9M
$46.7M
Price % of 52-Week High
6.95%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
8.74%
-0.74%
1-Year Price Total Return
-87.44%
-33.88%
Beta (5-Year)
-0.941
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.08
200-day SMA
Sell
Level
$0.39
Bollinger Bands (100)
Sell
Level
0.05 - 0.29
Chaikin Money Flow
Sell
Level
-819.7M
20-day SMA
Buy
Level
$0.05
Relative Strength Index (RSI14)
Buy
Level
66.82
ADX Line
Buy
Level
36.42
Williams %R
Sell
Level
-1.5038
50-day SMA
Buy
Level
$0.06
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
2.5B
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-0.7632)
Buy
Beneish M-Score
(Annual)
Level (-3.5502)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.5821)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services and product sales. Healthcare services generate the majority of revenue.
Stock Forecast FAQ
In the current month, NVOS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVOS average analyst price target in the past 3 months is --.
-
Where Will Novo Integrated Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Integrated Sciences share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Novo Integrated Sciences?
Analysts are divided on their view about Novo Integrated Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Integrated Sciences is a Sell and believe this share price will rise from its current level to --.
-
What Is Novo Integrated Sciences's Price Target?
The price target for Novo Integrated Sciences over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVOS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Integrated Sciences is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NVOS?
You can purchase shares of Novo Integrated Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Integrated Sciences shares.
-
What Is The Novo Integrated Sciences Share Price Today?
Novo Integrated Sciences was last trading at $0.09 per share. This represents the most recent stock quote for Novo Integrated Sciences. Yesterday, Novo Integrated Sciences closed at $0.09 per share.
-
How To Buy Novo Integrated Sciences Stock Online?
In order to purchase Novo Integrated Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 15
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 15
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
65
DJT alert for Jan 15
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
